Three drugs in major study to prove their capacity to slow aging
UT Health San Antonio is launching a groundbreaking $38 million human trial, VITAL-H, to assess whether three existing medications—rapamycin, semaglutide, and dapagliflozin—can help extend healthspan by slowing biological aging in humans. This study aims to enroll nearly 1,000 adults aged 60 to 65, marking a significant step in translating decades of aging research into practical clinical applications.
The trial is particularly noteworthy as it focuses on established drugs, allowing for a potentially faster transition from scientific inquiry to real-world therapeutic use. By measuring biological markers of aging and intrinsic capacity rather than just lifespan, VITAL-H seeks to address how well individuals can function as they age, emphasizing the importance of quality of life over mere longevity. This approach could reshape how aging interventions are developed and understood in clinical settings.
A key takeaway is the trial’s commitment to inclusivity, targeting a historically underrepresented Hispanic population in South Texas. This focus not only enriches the data but also aligns with the ethical imperative to ensure that aging research reflects diverse experiences. For a deeper dive into this promising study, I recommend exploring the full article.